Health
Trial: No Need to Stop RAS Inhibitors in COVID-19 – MedPage Today
REPLACE COVID trial supports findings from BRACE CORONA
Hospitalized COVID-19 patients may safely continue taking their angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the small REPLACE COVID trial.
The study’s primary hierarchical endpoint — a global rank score in which patients were ranked by the severity of their COVID disease course according to various biomarkers and clinical events, with a lower rank score meaning more severe COVID-19 hospitalization — was about the same whether people were…
-
General22 hours agoG7 agrees to avoid higher taxes for US, UK companies
-
Noosa News20 hours agoFood supply chain system costs farmers and regions millions of dollars
-
Business20 hours agoBuy and hold NDQ and these ASX ETFs for 10 years
-
General22 hours ago“Accumulation of defects”. A-G report scathing on Navy shipbuilding